{"id":395,"date":"2025-11-12T13:09:45","date_gmt":"2025-11-12T13:09:45","guid":{"rendered":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/?p=395"},"modified":"2025-11-12T13:09:45","modified_gmt":"2025-11-12T13:09:45","slug":"une-nouvelle-therapie-cellulaire-montre-des-resultats-prometteurs-contre-les-tumeurs-solides","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/une-nouvelle-therapie-cellulaire-montre-des-resultats-prometteurs-contre-les-tumeurs-solides\/","title":{"rendered":"Une nouvelle th\u00e9rapie cellulaire montre des r\u00e9sultats prometteurs contre les tumeurs solides"},"content":{"rendered":"

MiNK Therapeutics a annonc\u00e9 de nouveaux r\u00e9sultats cliniques montrant que son traitement<\/a> cellulaire exp\u00e9rimental, agenT-797, offre des r\u00e9ponses durables et une survie \u00e0 long terme chez les patients atteints de tumeurs solides qui n’ont pas r\u00e9pondu aux inhibiteurs de points de contr\u00f4le et \u00e0 d’autres traitements. Les r\u00e9sultats, pr\u00e9sent\u00e9s lors de la r\u00e9union annuelle de la Society for Immunotherapy of Cancer (SITC) en 2025, soulignent le potentiel de l’agenT-797 \u00e0 reprogrammer le syst\u00e8me immunitaire et \u00e0 restaurer la r\u00e9activit\u00e9 chez les patients atteints de cancers lourdement trait\u00e9s. Les patients ayant re\u00e7u la th\u00e9rapie en combinaison avec des agents anti-PD-1 ont obtenu une survie globale m\u00e9diane d’environ 23 mois. Ben Garmezy, directeur associ\u00e9 de la recherche en oncologie urog\u00e9nitale \u00e0 l’Institut de recherche Sarah Cannon, a d\u00e9clar\u00e9 : “Nous observons une activit\u00e9 clinique encourageante avec l’agenT-797.” Il a ajout\u00e9 qu’un patient atteint d’un cancer testiculaire m\u00e9tastatique a connu une r\u00e9mission compl\u00e8te pendant plus de deux ans. Le m\u00e9canisme de la th\u00e9rapie semble aller au-del\u00e0 de la destruction des cellules tumorales, avec des signes de r\u00e9activation immunitaire dans le microenvironnement tumoral. Cela pourrait marquer un changement dans la mani\u00e8re de traiter les cancers r\u00e9sistants aux immunoth\u00e9rapies. Jennifer Buell, pr\u00e9sidente et directrice g\u00e9n\u00e9rale de MiNK Therapeutics, a expliqu\u00e9 : “L’agenT-797 continue de fournir ce que les inhibiteurs de points de contr\u00f4le seuls ne peuvent pas.” Elle a d\u00e9clar\u00e9 que les donn\u00e9es soutiennent l’id\u00e9e que les cellules iNKT repr\u00e9sentent une nouvelle classe de th\u00e9rapie restauratrice immunitaire. Avec un profil de s\u00e9curit\u00e9 favorable et une activit\u00e9 constante dans diff\u00e9rents types de tumeurs, l’agenT-797 est maintenant pr\u00eat \u00e0 entrer en phase 2 d’essais cliniques. MiNK croit que la th\u00e9rapie pourrait red\u00e9finir le traitement pour les patients ayant peu d’options, offrant de l’espoir dans les cas o\u00f9 l’immunoth\u00e9rapie conventionnelle a \u00e9chou\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"

MiNK Therapeutics a annonc\u00e9 de nouveaux r\u00e9sultats cliniques montrant que son traitement cellulaire exp\u00e9rimental, agenT-797, offre des r\u00e9ponses durables et […]<\/p>\n","protected":false},"author":1,"featured_media":396,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-395","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=395"}],"version-history":[{"count":1,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/395\/revisions"}],"predecessor-version":[{"id":413,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/395\/revisions\/413"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media\/396"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}